ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
83.325
-0.26%
US Dollar vs AUD
1.53071
-0.02%
Bitcoin
59,032.00
1.36%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) News

ATNM

Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:ATNM
DateTimeSourceHeadlineSymbolCompany
18/04/202422:00PR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
01/04/202423:00PR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
26/03/202422:18PR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
11/03/202422:30PR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
26/02/202423:30PR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
23/02/202423:30PR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
10/02/202408:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
06/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
03/02/202409:03Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
02/01/202423:30PR Newswire (US)Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®AMEX:ATNMActinium Pharmaceuticals Inc
30/12/202309:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
30/12/202309:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
30/12/202309:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
30/12/202309:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
30/12/202309:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/12/202300:15PR Newswire (US)Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationAMEX:ATNMActinium Pharmaceuticals Inc
11/12/202323:45PR Newswire (US)Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAMEX:ATNMActinium Pharmaceuticals Inc
09/12/202300:00PR Newswire (US)Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionAMEX:ATNMActinium Pharmaceuticals Inc
02/12/202309:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
10/11/202309:09Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
10/11/202309:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
06/11/202323:30PR Newswire (US)Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsAMEX:ATNMActinium Pharmaceuticals Inc
03/11/202307:15PR Newswire (US)Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023AMEX:ATNMActinium Pharmaceuticals Inc
03/11/202300:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
03/11/202300:05PR Newswire (US)Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
04/10/202322:30PR Newswire (US)Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
27/09/202323:05PR Newswire (US)Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
07/09/202322:40PR Newswire (US)Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOAMEX:ATNMActinium Pharmaceuticals Inc
31/08/202321:00PR Newswire (US)Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
21/08/202321:00PR Newswire (US)Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressAMEX:ATNMActinium Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:ATNM

Your Recent History

ASX
MQG
Macquarie
NYSE
MCD
McDonalds
ASX
RIO
Rio Tinto
NASDAQ
GOOGL
Alphabet
ASX
QBE
QBE Insurance
NYSE
KO
Coca Cola
NYSE
VZ
Verizon Communications
ASX
ANZ
Australia And New Zealan...
NASDAQ
QQQ
Invesco QQQ Trust Series 1
ASX
TLS
Telstra
ASX
WPL
Woodside Petroleum
ASX
ORG
Origin Energy
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
ASX
CSL
CSL
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved